NCT01205451View on ClinicalTrials.gov

A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity

PHASE3CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
Spasticity, Post-Stroke
Interventions
DRUG

Botulinum toxin type A

Botulinum toxin type A

Trial Locations (13)

100050

GSK Investigational Site, Beijing

100068

GSK Investigational Site, Beijing

100730

GSK Investigational Site, Beijing

110001

GSK Investigational Site, Shenyang

150001

GSK Investigational Site, Haerbin

200025

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

215004

GSK Investigational Site, Suzhou

310016

GSK Investigational Site, Hangzhou

430060

GSK Investigational Site, Wuhan

610041

GSK Investigational Site, Chengdu

Unknown

GSK Investigational Site, Guangzhou

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY